The diagnosis and management of idiosyncratic drug‐induced liver injury by Hassan, Ammar & Fontana, Robert J.
Liver International. 2019;39:31–41.	 wileyonlinelibrary.com/journal/liv	 	 | 	31© 2018 John Wiley & Sons A/S. 
Published by John Wiley & Sons Ltd
1  | OVERVIE W
Idiosyncratic drug- induced liver injury (DILI) is an uncommon but 
important cause of liver disease worldwide. To make a diagnosis of 
DILI requires a high index of suspicion after ruling out more common 
causes of liver injury, such as viral hepatitis, alcohol, autoimmune 
hepatitis and pancreaticobiliary disease. The lack of a confirmatory, 
objective laboratory test to identify the culprit agent remains prob-
lematic, particularly in patients taking multiple medications or herbal 
and dietary supplements (HDS) and in those with underlying liver 
disease. Nonetheless, a careful review of the temporal association 
between medication use and the laboratory and clinical profile at 
DILI onset allows one to confidently make a diagnosis of DILI.1 The 
spectrum of liver injury in DILI patients ranges from mild to moder-
ate serum alanine aminotransferase (ALT) or alkaline phosphatase 
(ALK) level elevations with or without jaundice that resolves within 
6 months of drug discontinuation in most patients. However, some 
patients may develop rapidly progressive acute liver failure (ALF) or 
evolve into a smouldering chronic liver injury. A liver biopsy can help 
exclude competing causes of liver injury and help identify character-
istic histological features associated with the suspect drug as well as 
provide prognostic information.2
Two recent population- based studies from Europe estimate 
that the annual incidence of DILI is 14 to 19 cases per 100 000 
inhabitants.3,4 However, many experts believe that the actual 
incidence of DILI is higher due to the difficulty in establishing a 
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Abstract
Drug- induced liver injury (DILI) is an uncommon but important cause of liver disease 
that can arise after exposure to a multitude of drugs and herbal and dietary supple-
ments. The severity of idiosyncratic DILI varies from mild serum aminotransferase 
elevations to the development of severe liver injury that can progress to acute liver 
failure resulting in death or liver transplantation within days of DILI onset. Chronic 
liver injury that persists for more than 6 months after DILI onset is also becoming 
increasingly recognized in up to 20% of DILI patients. Host demographic (age, gender, 
race), clinical and laboratory features at DILI onset have been associated with the 
severity and outcome of liver injury in DILI patients. In addition to cessation of the 
suspect drug, other medical interventions including the use of N- acetylcysteine and 
corticosteroids in selected patients have shown some clinical benefit, but additional 
prospective studies are needed. A number of promising diagnostic, prognostic and 
mechanistic serum and genetic biomarkers may help improve our understanding of 
the pathogenesis and treatment of idiosyncratic DILI.
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diagnosis and under- reporting. The implicated agents that cause 
DILI vary substantially around the world (Table 1). Although an-
tibiotics are the most commonly implicated agents in many DILI 
series, the most common individual antimicrobial agent varies, 
with antitubercular agents (particularly isoniazid) being most fre-
quently implicated in Asian countries while amoxicillin- clavulanate 
is the most common suspect drug in both the USA and Spain.5-7 
Herbal and dietary supplements (HDS) are also widely used in 
many parts of the world and have accounted for a substantial and 
increasing proportion of DILI cases in Asia as well as Europe and 
North America.8 The Drug-Induced Liver Injury Network (DILIN) 
recently reported that HDS products were the second leading 
cause of DILI in the USA accounting for 16% of cases.6 In compar-
ison, antihypertensives, antidiabetic agents and hypolipidaemic 
agents (eg statins) are infrequently (< 5%) implicated as a cause of 
DILI despite their widespread use.
2  | SE VERE DILI
DILI patients with severe nausea and vomiting, coagulopathy or hypo-
glycaemia may require hospitalization. Patients with acute hepatitis and 
elevated prothrombin time or international normalized ratio (INR) levels 
without mental status changes are commonly categorized as having se-
vere acute liver injury (ALI). A large case series of 386 hospitalized ALI 
patients reported by the US Acute Liver Failure Study Group (ALFSG) 
demonstrated a 3- week transplant- free survival rate of 87% in patients 
with idiosyncratic DILI.9 In contrast, hospitalized patients with an el-
evated INR who develop hepatic encephalopathy have ALF and a much 
higher mortality.10 In the USA, idiosyncratic DILI accounts for 13% of 
all ALF cases and is associated with a 3- week transplant- free survival 
rate of only 27%.11 The most commonly implicated agents leading to 
ALF- related DILI in the USA are isoniazid, bactrim, nitrofurantoin and 
HDS products.12 However, emergency liver transplantation offers an 
excellent survival benefit in these patients with an 88% 3- week sur-
vival after transplantation.12 Series from countries with limited access 
to transplantation also demonstrate a low rate of spontaneous survival 
in ALF patients with DILI (9% vs 17%) (Table 2).13
Key points
• Idiosyncratic drug-induced liver injury is an infrequent 
but important cause of both acute and chronic liver 
injury.
• Host demographic, clinical and laboratory features at 
DILI onset are associated with the severity and outcome 
of liver injury in DILI patients.
• Management of suspected DILI after drug discontinua-
tion is largely supportive, but pilot studies suggest that 
N-acetylcysteine and corticosteroids may prove safe 
and effective in selected patients.
• There are a number of promising diagnostic, prognostic 
and mechanistic serum and genetic biomarkers that may 
improve our understanding of the pathogenesis and 
treatment of idiosyncratic DILI
TA B L E  1   Aetiologies and outcomes of DILI in studies from around the world
Series
Chalasani et al 
(ref6)
Andrade et al 
(ref7)
Bjornsson et al 
(ref3)
Suk et al 
(ref8) Takikawa et al (ref85)
Devarbhavi et al 
(ref13)
Country USA Spain Iceland Korea Japan India
Patients (n) 899 461 96 371 1,676 313
Mean age (years) 49 53 40- 59 49 55 39
% female 59% 49% 56% 63% 57% 42%
Agents implicated Antimicrobials 
(45%)
Antimicrobials 
(32%)
Antimicrobials 
(37%)
HDS 
(28%)
Antimicrobials (14%) Antimicrobials (31%)
HDS (16%) CNS drugs (17%) HDS (16%) Non- 
HDS 
(17%)
CNS drugs (10%) CNS drugs
CVS agents (10%) Musculoskeletal 
(17%)
NSAIDs (6%) Pills, 
powder 
(6%)
HDS (10%) (11%)
%HC/Chol/Mix 54%, 23%, 23% 58%, 20%, 22% 42%, 32%, 26% 76%, 
9%, 
15%
59%, 21%, 20% 58%, 23% 19%
% Txp or Death 9% 7% 1% 2% 2% 3%
% Chronic 17% 6% 7% NA NA NA
HC, hepatocellular; Chol, cholestatic; Mix, mixed; CNS, central nervous system; NSAID, nonsteroidal anti- inflammatory drugs; HDS, herbal and dietary 
supplements.
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In the USA, liver transplant candidates with chronic liver failure 
are prioritized for deceased donor liver transplantation (LT) using the 
Model for End- Stage Liver Disease (MELD) scoring system that is de-
rived from bilirubin, INR, creatinine and sodium levels. However, highly 
selected patients in the intensive care unit with new- onset ALF of any 
aetiology are granted a MELD exception score of 40 and have greater 
access to emergency liver transplantation as a “Status 1” patient.14 In 
Asia where access to deceased donor LT is more limited, some centres 
consider living donor LT for selected ALF patients.15 Although living 
donor LT can be safely performed for ALF patients with survival rates 
similar to those undergoing deceased donor LT, concerns remain about 
whether donor candidates can be safely evaluated in a highly com-
pressed time frame without undue coercion.14,15
3  | OUTCOMES IN PATIENTS WITH 
SE VERE DILI
Recently, DILIN reported on 24- month outcomes in 1089 consecu-
tive high causality DILI patients enrolled into the ongoing Prospective 
registry study between 2003 and 2015.16 This study showed a 10% 
fatality/transplant rate with the majority of adverse outcomes (92%) 
occurring within 6 months of DILI onset. However, not all cases of 
severe DILI rapidly progress to the loss of significant hepatic func-
tion that culminates in death or liver transplantation. In addition, ALF 
secondary to DILI can have a delayed or subacute presentation, with 
hepatic encephalopathy manifesting up to 26 weeks after jaundice 
onset.17
4  | DEMOGR APHIC S OF PATIENTS WITH 
SE VERE DILI
In a recent study of 771 Spanish DILI patients, 64% of those who 
progressed to ALF were female18 while an even greater percentage 
(70%) of fulminant DILI cases were women in the ALFSG cohort of 
113 patients.12 However, the DILIN prospective registry study failed 
to show a significant association between female gender and out-
comes in 899 consecutive DILI cases.19 The basis for a possible gen-
der predisposition to severe DILI may be related to differences in 
drug metabolism or hepatic adaptation to injury and regeneration.
Prior studies have also demonstrated that the age of ALF patients 
is inversely associated with the likelihood of liver regeneration and 
recovery. In addition, older individuals with DILI appear to be at in-
creased risk for adverse clinical outcomes.16 There are growing data 
on the role of racial and ethnic differences as well in patients with 
DILI.20,21 A recent publication from DILIN found that not only did the 
causative agents differ between African Americans and Caucasians, 
African Americans were also more likely to have more severe cuta-
neous reactions and a greater degree of liver injury leading to worse 
outcomes.20 The relationship between alcohol consumption and 
DILI susceptibility and outcome remains unclear. In a recent study 
of 1198 DILIN patients, heavy alcohol consumers had significantly 
higher serum ALT and total bilirubin levels compared to nondrinkers 
but the risk of a fatal outcome was not increased.22
In both animal and human studies, diabetes mellitus is an inde-
pendent risk factor for severe DILI outcomes.19,23-25 For example, one 
recent study demonstrated that overweight or obese patients were 
more likely to develop acetaminophen hepatotoxicity.23 In addition, 
a recent study of 259 patients with inflammatory bowel disease re-
ceiving immunosuppressants demonstrated that those with baseline 
steatosis were more likely to develop liver injury.24 The mechanism 
by which diabetic patients and those with underlying hepatic ste-
atosis may be more susceptible to DILI remains unclear but possibly 
related to altered cytochrome- P450 or transporter expression re-
sulting in aberrant drug pharmacokinetics or disposition. In addition, 
differences in hepatocyte autophagy, intrahepatic oxidative stress 
and ferroptosis in the setting of hepatic steatosis may play a role.25
Recent studies also demonstrate that individuals with certain 
class I and II human leucocyte antigen (HLA) alleles may be at in-
creased risk of developing idiosyncratic DILI such as those with HLA- 
A*33:01 developing terbinafine and fenofibrate DILI.21 However, 
there is less evidence supporting a link between specific genetic 
polymorphisms and poor outcomes in DILI patients.26
5  | INITIAL L ABOR ATORY FE ATURES IN 
PATIENTS WITH SE VERE DILI
Serum AST and ALT elevations do not reliably correlate with the de-
gree of hepatic impairment, while increases in the INR are more in-
dicative of loss of hepatic functional mass. Nonetheless, the degree 
of ALT elevation, as well as the serum AST/ALT ratio, was associated 
with the development of ALF and chronic liver injury in some DILI 
patients.21,26-28
In 1978, the late Hyman Zimmerman noted that the development 
of jaundice (ie total bilirubin >2.5 mg/dL) in DILI patients with acute 
hepatocellular liver injury (ie serum ALT > 3× upper limit of normal 
(ULN)) was associated with an estimated mortality of 10%.27 This 
observation has been clinically evident in retrospective studies of 
TA B L E  2   Outcomes of patients with ALF due to idiosyncratic 
DILI
Series
Reuben et al 
(ref11)
Hillman et al 
(ref86)
Zhao 
et al 
(ref87)
Country USA USA China
Total ALF cases 1198 2626 117
% ALF due to DILI 11% 8% 44%
% female 71% 33% 54%
% spontaneous 
recovery
27% 35% 23%
% requiring Txp 42% 36% NA
% overall 
mortality
33% 31% 38%
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DILI	 patients	 from	 Sweden	 and	 Japan.3,29 However, the utility of 
“Hy’s law” is limited in the clinical setting due to its low specificity 
for death.30 To overcome this limitation, alternative models utilizing 
laboratory parameters at DILI onset have been developed to more 
accurately prognosticate clinical outcomes. These models include 
the Nr model (ALT or AST, whichever is highest, X ULN/ALP X ULN), 
which showed the best sensitivity and specificity in predicting ALF 
in the setting of severe DILI in a Spanish cohort18 (Table 3).
Interestingly in the ongoing DILIN registry study, 64% of the 
deaths were primarily attributed to the DILI event while DILI had 
a secondary or contributory role in 14% and a nonhepatic cause of 
death was identified in the remaining 20% with advanced medical 
comorbidities (eg cancer, heart failure). Apart from older age, no 
significant demographic differences were seen between those with 
and without fatal outcomes. The study also assessed several dif-
ferent prognostic scores (Hy’s Law, nR Hy’s Law and MELD) at DILI 
onset as a predictor of liver- related death/transplant. The area under 
the receiver operating curve (AUROC) to predict mortality from DILI 
was 0.60 for Hy’s law, 0.73 for nR Hy’s Law, and 0.83 with a MELD 
score of >19 (Table 3).
6  | MANAGEMENT OF SE VERE DILI
Making a diagnosis of DILI requires a high index of suspicion due to 
the wide range of clinical manifestations and large number of cul-
prit agents that can cause DILI. In that regard, utilizing resources 
such as the LiverTox database can provide clinicians with up- to- date 
diagnostic criteria and published clinical, laboratory and histologi-
cal features of DILI attributed to over 900 drugs and 30 HDS prod-
ucts.31 This e- textbook also includes annotated references and has 
new sections describing hepatotoxicity from selected HDS products 
(see https://livertox.nih.gov). A drug likelihood scale has also re-
cently been developed that categorizes the hepatotoxicity potential 
of drugs according to the total number of published reports of bon-
afide hepatotoxicity with that agent.32
The current recommended treatment for all patients with DILI 
is to immediately withhold the offending drug once the diagnosis 
is suspected. Early discontinuation of the offending agent may help 
prevent the development and progression of further liver injury. 
However, the liver damage in many DILI patients is perpetuated 
after drug cessation via activation of the innate immune system and 
the development of a cytokine- driven acquired immune response.28 
Therefore, avoidance of exposure to other potentially hepatotoxic 
medications and substances, including alcohol, is also recommended 
for all DILI patients. Furthermore, oral enteral nutrition may be con-
sidered in severely ill hospitalized patients with inadequate caloric 
intake and fat- soluble vitamin replacement is advisable in patients 
with prolonged cholestasis at risk of developing micronutrient 
deficiencies.33
Gastric lavage and administration of activated charcoal that are 
used in acute acetaminophen overdose31 and heavy metal poison-
ing34 do not have a role in the primary management of idiosyncratic 
DILI as most drugs have been metabolized and cleared from the body 
by the time that DILI becomes apparent. While N- acetylcysteine 
(NAC) is of proven benefit in the treatment of acetaminophen 
overdose, recent data also support its use in preventing the devel-
opment of ALF due to other drugs. A randomized controlled trial 
showed that prophylactic use of oral NAC reduced the incidence of 
hepatotoxicity associated with the use of antituberculosis medica-
tions.35 Another double- blind randomized controlled study in 173 
patients with non- acetaminophen–related ALF demonstrated that 
those treated with NAC had significant improvement in transplant- 
free survival as well as lower bilirubin and ALT levels compared to 
placebo- treated patients.36 Similar findings have been reported in 
a recently published meta- analysis.37 However, use of NAC in non- 
APAP–related ALF in children was not efficacious and therefore is 
not recommended.38
TA B L E  3   Models to predict adverse outcomes in the setting of severe DILI
Robles- Diaz M et al18
ALF/Txp = 32 (4.1%) of 771 DILI patients
Model ALT > 3 × ULN + TBL > 2 × ULN (Hy’s law) R	≥	5	+TBL	>	2	×	ULN Nr	≥	5	+	TBL	>2	×	ULN	
(New Hy’s law)
Sensitivity 90% 83% 90%
Specificity 44% 67% 63%
AUROC 0.67 0.74 0.77
Hayashi et al16
ALF/Txp = 68 (6.2%) of 1089 DILI patients
Model ALT > 3 × ULN + TBL > 2 × ULN (Hy’s law) Nr	≥	5	+	TBL	>2	×	ULN	(New	Hy’s	law) MELD score
Sensitivity 52% 79% 90%
Specificity 71% 69% 75%
AUROC 0.60 0.73 0.83
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Corticosteroids have been used in the setting of drug- induced 
hypersensitivity syndromes for many years.39 In addition, pro-
longed high- dose corticosteroids are recommended in patients 
with drug- related eosinophilic systemic syndrome (DRESS) who 
frequently have concomitant hepatic biochemical abnormalities.40 
However, not all cases of drug- induced hypersensitivity reactions 
respond to corticosteroid administration, particularly in the set-
ting of prolonged jaundice.41 Corticosteroids have also been used 
in the treatment of DILI secondary to the use of tyrosine kinase 
inhibitors.42 Lastly, ipilimumab, a monoclonal antibody that in-
hibits cytotoxic T- lymphocyte antigen- 4 (CTLA- 4), and the PD- 1 
inhibitors, nivolumab and pembrolizumab, are increasingly being 
used in the treatment of solid organ tumours.43 These agents 
can cause a moderate- to- severe hepatitis in up to 10% to 20% of 
treated patients that present with severe acute hepatocellular in-
jury within 6 months of treatment. Many of the patients in clinical 
trials with liver injury were treated with high- dose corticosteroids 
and/or mycophenolic acid once the serum ALT exceeded 3 × ULN. 
However, liver biopsy may be of benefit in oncology patients with 
suspected DILI to insure other causes of liver injury are excluded 
and stratify the risk for immune- mediated versus other histologi-
cal phenotypes of injury44,45 (see Figure 1).
The utility of ursodeoxycholic acid (UDCA) is largely provided via 
case reports and observational studies in patients with cholestatic 
DILI. Uncontrolled data suggest that UDCA may hasten liver injury 
recovery46 or attenuate the risk of developing vanishing bile duct 
syndrome in some patients.47 However, more recent studies from 
DILIN have failed to demonstrate similar benefits.19 Bile acid binding 
resins such as cholestyramine are frequently used in DILI patients 
with severe cholestasis and pruritus.48 These agents may also be ben-
eficial in the “washout” of hepatotoxic drugs that have a long half- life 
and undergo enterohepatic circulation, such as leflunomide.49
Various nonpharmacological treatment strategies have also been 
studied in DILI patients. Silymarin is a combination of three flavonoids 
(silybin, silydianin and silychristin) that are the active ingredients of 
milk thistle which has shown promise in animal models of DILI.50 
However, prophylactic studies in patients receiving antituberculosis 
medications have been conflicting and inconclusive.51 Glycyrrhiza 
F I G U R E  1   A 55-year-old man with metastatic melanoma to the liver was prescribed ipilimumab (IPI) and nivolumab (NIV) infusions at day 
1 and day 21.   At day 60, he presented to the emergency room with weakness and hypotension with ALT 460 IU/L, alk phos 255 IU/L and 
total bilirubin of 2.2 mg/dl.  Initial ANA, SmAb and quantitative immunoglobulins were normal and a liver biopsy on day 64 after DILI onset 
showed (A) Active hepatitis and steatosis. The portal and lobular inflammation was composed mostly of macrophages and lymphocytes. (B). 
There were also multiple granulomas in the lobules, many with fibrin-ring granuloma morphology characterized by a central lipid vacuole, 
surrounding ring of fibrin, and epithelioid macrophages mixed with lymphocytes (arrowheads).  MRI of the liver confirmed progression of his 
intrahepatic metastases and he was discharged home on high dose steroids.  Due to disease progression (C) he was given another infusion of 
nivolubumab alone at day 156. However, his ALT increased to 170 IU/l and prednisone was increased to 100 mg per day and mycophenolate 
was added.  However, disease progressed further with portal vein thromboses and he died at day 263 of metastatic disease with ALT of 135 
U/L and total bilirubin of 5.8 mg/dl.  (hematoxylin-eosin stain, original magnification x100 [A] and x400 [B]). Photomicrographs courtesy of 
Karen Choi, MD, University of Michigan.
Liver biopsy 
Corticosteroids
NIV
IPI + NIV
(C)
(A)
(B)
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glabra is a licorice derivative that has been used as a single agent 
or in combination with cysteine and glycine for the management of 
DILI,	particularly	in	India	and	Japan.52 A combination of monoammo-
nium glycyrrhizinate- glycine- L- cysteine HCl (Monofit 20 mL/day) is 
also	commonly	used	to	treat	acute	DILI	in	Japan.53 Glycyrrhizin is an 
aqueous extract of the licorice root and has exhibited in vitro hepa-
toprotection through cell membrane stabilization.54 An European 
randomized controlled trial of glycyrrhizin showed improvement in 
serum ALT and hepatic necroinflammation and fibrosis in patients 
with chronic hepatitis C who were nonresponders to interferon.55 
Similarly, studies from Asia have shown beneficial effects with gly-
cyrrhizin in patients with chronic hepatitis B.56,57
7  | CHRONIC DILI
While most cases of DILI resolve after discontinuation of the suspect 
drug, a minority of patients may go on to develop chronic liver injury. 
There is currently a lack of a consensus definition of what constitutes 
chronic DILI. DILIN has defined chronic DILI as persistent elevation 
Chronic DILI 
subtype
Commonly involved 
drugs Clinical features
Autoimmune 
DILI (AI- DILI)
Nitrofurantoin 
Minocycline 
Statins 
Methyldopa
•  Reactive hepatic metabolites bind to cellular 
proteins leading to immune activation.
•  Frequency of AI-DILI among those diagnosed 
with AIH is 9-13%.88
• Diagnosis of AI-DILI remains difficult as it 
presents similarly to sporadic AIH regarding 
serum ALT levels and presence of autoantibodies 
(ANA, SMA)89
• Immunosuppressive therapy indicated if injury 
does not resolve with drug cessation.90
Drug- induced 
hepatic 
steatosis
Microvesicular 
steatosis: 
Valproic acid 
Diltiazem 
Interferon 
NSAIDs 
Hypervitaminosis 
A 
Macrovesicular 
Steatosis: 
Oestrogen 
Tamoxifen 
Both macro- and 
microvesicular 
Steatosis: 
Amiodarone 
Methotrexate 
Didanosine
• (Microvesicular steatosis) Mitochondrial 
dysfunction with inhibition of beta-oxidation of 
fatty acids leads to diffuse deposition of lipid 
droplets in hepatocytes without displacement of 
nucleus.91
• With extensive mitochondrial dysfunction, 
systemic complications such as hypoglycaemia, 
lactic acidosis and encephalopathy.92
• (Macrovesicular steatosis) Intracellular drug 
deposition can lead to accumulation of intracel-
lular phospholipids and/or altered hepatic lipid 
trafficking.
• Large intracellular fat deposits with displacement 
of nucleus.93
Vanishing bile 
duct 
syndrome 
(VBDS)
Amoxicillin 
Ciprofloxacin 
Azithromycin 
Allopurinol 
Carbamazepine
• Typically occurs after a bout of severe cholestatic 
hepatitis.94
• Progressive loss of intrahepatic bile ducts with 
cholestasis that can lead to hepatic failure.95
Drug- induced 
nodular 
regenerative 
hyperplasia 
(DI- NRH)
Thiopurines 
Platinum- based 
chemotherapy 
Hypervitaminosis 
A 
antiretroviral drugs 
(didanosine, 
stavudine)
• Latency of 6 months or more, minimal elevations 
in ALT and ALK <3 × ULN with clinical, radiologi-
cal or endoscopic features of portal 
hypertension.
• Liver biopsy shows nodularity with no or minimal 
inflammation.96
Drug- induced 
peliosis 
hepatitis
Anabolic steroids 
Oral contraceptive 
(Oestrogen) 
Tamoxifen 
Azathioprine
• Acquired vascular disorder with sinusoidal 
dilation and loss of endothelial barrier.97
• Usually asymptomatic, mild ALT elevation but can 
present with vascular collapse due to intraab-
dominal bleeding98 or progression to cirrhosis.99
TA B L E  4   Phenotypes of chronic DILI
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of serum ALT, ALK or total bilirubin levels >1.25 × ULN or the baseline 
if abnormal at 6 months after DILI onset.58 The DILI Expert Working 
Group use a shorter time period of 3 months of continued liver injury 
after recognition to classify a case as chronic DILI.59 In contrast, the 
Spanish DILI registry defines chronic DILI as persistently elevated 
aminotransferase levels for more than 3 months after drug with-
drawal in patients with hepatocellular injury or persistently elevated 
liver biochemistries for more than 6 months in patients with chole-
static/mixed liver injury.7 A more recent analysis from the Spanish 
group suggested that persistence of liver biochemical abnormalities 
at 1 year after DILI onset may be more clinically relevant.60
Regardless of the definition of chronic DILI, a substantial number 
of patients who experience acute DILI progress to chronic liver injury 
during follow- up. The incidence of chronic DILI in DILIN, the Spanish 
registry and Iceland was reported at 19%, 6% and 7% respectively.3,6,7 
In the DILIN study, chronic DILI was more commonly seen in African 
American patients and those with a cholestatic laboratory profile 
at presentation.6 Although a large number of drugs have been im-
plicated in the development of chronic DILI, the most commonly 
identified agents in the DILIN study were amoxicillin- clavulanic acid, 
trimethoprim- sulfamethoxazole and azithromycin and antibiotics 
were over- represented in the Spanish study as well.6,60 The pheno-
types of persistent liver injury after acute DILI encompass a spectrum 
of clinical disorders (Table 4). Autoimmune- like DILI and cholestatic 
liver injury with progressive loss of intrahepatic bile ducts (vanishing 
bile duct syndrome) are well documented but infrequent long- term 
clinical and histological subtypes of chronic DILI.59 Drugs that are 
more likely to lead to an autoimmune phenotype include minocycline, 
methyldopa, nitrofurantoin and hydralazine. However, whether drug- 
induced autoimmune hepatitis can be reliably distinguished from 
Biomarker Clinical significance Characteristics/limitations
Liver injury markers
Sorbitol dehydroge-
nase (SDH)
Marker of hepatocyte injury • Early marker of acute liver injury
• Nonspecific
Glutathione 
S- transferase 
alpha (GSTα)
Elevated in liver injury (centrilobular hepatocytes) and 
renal injury
• Early marker of acute liver injury (serum)
• Early marker of acute kidney injury (urine)
Bile acids Elevated levels of endogenous bile acids due to impaired 
excretion from injured hepatocytes
• More specific indicator of liver injury than bilirubin
• Elevated in other liver diseases (IHCP)
Glutamate 
dehydrogenase 
(GLDH)
Reflective of mitochondrial dysfunction • Elevated in chronic liver disease not due to DILI
Micro- RNAs
miR- 122
miR- 192
Noncoding, liver- specific RNAs released from damaged 
hepatocytes
• Elevated levels secondary to acute and chronic liver 
injury
• Further validation analytical methods needed
Mechanistic biomarkers
HMGB1 Marker of tissue necrosis • Not liver specific
Acetylated HMGB1 Marker of activation of innate immune system • Not liver specific
• Requires mass spectrometry
Cytokeratin 18 
fragments
Marker of tissue apoptosis (caspase- cleaved proteins)
M- 30 Marker of apoptosis • Not liver specific
• Prognostic validation ongoingM- 65 Marker of total apoptosis and necrosis
Serum Cys- APAP 
adducts
Sensitive and specific marker of acetaminophen 
overdose
• Point of care testing in development
• Therapeutic dosing vs intentional/unintentional 
overdose
Metabolomics
Urine or serum 
metabolome
Measurement of endogenous metabolites generated in 
relation to drug exposure
• Still exploratory
• Confounding by dietary, environmental, microbiome 
factors
Genetic polymorphisms
HLA- B * 57:01
HLA- A * 33:01
HLA- B * 35:02
Flucloxacillin DILI (odds ratio 80)
Mixed/ cholestatic DILI susceptibility (odds ratio 5.0)
Terbinafine DILI (odds ratio 40)
Minocycline DILI (odd ratio 29)
• Strong NPV in flucloxacillin-treated Caucasians with 
unexplained cholestasis
• Identified with DILI due to multiple drugs in a large 
Caucasian cohort
• Requires validation in other cohorts
TA B L E  5   Proposed DILI biomarkers
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sporadic AIH based upon liver histology and the types of infiltrating 
leucocytes, HLA genotype or outcomes after steroid withdrawal re-
main unclear.61-63 A recent systemic review on chronic DILI described 
drug- induced fatty liver, focal nodular hyperplasia and peliosis hepa-
titis as additional subtypes that are increasingly recognized in long- 
term cancer survivors who received chemotherapy.
Currently, there are limited data on the long- term clinical outcomes 
of patients who develop chronic DILI.60,64,65 A paper from DILIN that 
prospectively followed 99 patients with evidence of liver injury 6 months 
after DILI onset found that the majority (75%) had persistent liver dam-
age 12 months after DILI onset. Older patients and those who had higher 
serum ALK levels at presentation were more likely to continue to have 
evidence of liver injury 12 months after DILI onset. Importantly, in those 
patients with baseline and follow- up liver biopsies, fibrosis progression 
was seen in two- thirds of cases. These findings suggest that patients 
with chronic DILI should be followed up closely to assess for late clinical 
and histological progression of liver disease.66
8  | NE W BIOMARKERS FOR DILI 
DIAGNOSIS AND PROGNOSIS
Establishing a diagnosis of DILI requires the exclusion of more com-
mon causes of liver injury, a temporal association between drug 
exposure and DILI onset, and compatible laboratory, clinical and 
pathological features during follow- up.67 Causality assessment in 
DILI provides a semiquantitative estimate of the likelihood that a 
drug was involved in the observed illness and is essentially based 
upon “circumstantial evidence.” To improve standardization and 
reproducibility in DILI diagnosis, liver- specific causality assess-
ment instruments such as the Roussel Uclaf Causality Assessment 
Method (RUCAM) were developed from a consensus opinion of an 
expert panel in 1990 and “validated” from a group of 49 published 
DILI cases which had been rechallenged and compared to 28 con-
trols.68 Limitations of the RUCAM include ambiguous instructions 
for use, reliance on rechallenge, and lack of evidence supporting the 
weighting and selection of domains. In addition, the RUCAM per-
forms poorly in the most severe cases of DILI that resulted in death, 
transplant or prolonged cholestasis mostly due to the lack of dechal-
lenge data.7 DILIN has developed causality assessment scales (range 
1 = definite to 5 = unlikely) based on expert opinion that are more 
reliable and reproducible than the RUCAM.69,70 However, expert 
opinion is not generalizable and requires knowledge of prior cases of 
liver injury for pattern recognition.
Currently available laboratory markers of liver injury (ie serum AST, 
ALT, ALK) are not sensitive or specific enough to detect early DILI nor 
are they able to reliably prognosticate the outcomes of such injury. This 
has led to a great interest in identifying novel serum biomarkers for 
DILI diagnosis and prognosis.71 Biomarkers in development broadly fall 
into three categories: (A) dynamic liver injury markers that identify and 
quantify the degree of hepatocyte damage, (B) mechanistic markers 
that aim to elucidate the underlying cause of liver injury and (C) prog-
nostic markers.67 Serum biomarkers such as sorbitol dehydrogenase 
(SDH),72 glutathione S- transferase73 and glutamate dehydrogenase 
(GLDH)74 have been studied in various forms of liver injury, including 
ischaemic hepatitis and DILI (Table 5). In particular, GLDH and micro- 
RNA- 122 (miR- 122) show promise as being more sensitive and specific 
biomarkers of liver injury than ALT, with promising results in animal 
models and clinical studies in patients with liver damage from various 
aetiologies.75 However, further replication and validation studies are 
needed before these can be incorporated into clinical practice.
The nature of hepatocyte death, necrosis vs apoptosis, has been 
shown in animal models to be associated with a worsened laboratory 
and clinical course in the former. To this end, the use of an “apoptotic 
index” (AI) based on serum biomarkers has been proposed to estimate 
the relative contributions of apoptosis and necrosis in the setting of 
liver injury. This index utilizes assessment of the ratio of full- length cy-
tokeratin 18 (K18) that is passively released from the liver in the setting 
of hepatocyte necrosis and caspase- cleaved cytokeratin 18 (ccK18) 
formed by caspase- mediated cleavage during apoptosis. Quantification 
of both total and caspase- cleaved K18 has been shown to exhibit en-
hanced sensitivity in the detection of DILI when compared to serum 
ALT.76 The apoptosis index has also been studied as a prognostic tool, 
with a lower value (greater necrosis) indicative of a poorer likelihood of 
survival in patients with acetaminophen overdose.77 A pilot study from 
DILIN also suggests that a lower apoptosis index may be associated 
with poorer outcomes in patients with idiosyncratic DILI.78
An important step in the presumed pathogenesis of idiosyncratic 
DILI is the release of damage- associated molecular patterns (DAMPs) 
that activate innate immune cells to release cytokines and chemok-
ines that draw inflammatory cells into the liver, a prerequisite for a 
targeted, adaptive immune attack of the liver. Biomarkers reflecting 
the initiation and maintenance of an immune- based inflammatory 
process secondary to drug exposure can not only help in the earlier 
identification of such injury (before liver enzyme elevation) but may 
also help differentiate transient elevation of liver enzymes reflecting 
adaptation from the development of significant DILI. In this regard, 
high mobility group box 1 (HMGB1), a DAMP that can be detected 
in the serum in various isoforms demonstrates great promise.79-81
9  | GENETIC BIOMARKERS
Due to its low incidence in the general population, genetic variation in 
host receptors, metabolic pathways and immune response have been 
implicated in DILI pathogenesis. The first successful genomewide as-
sociation study (GWAS) in DILI identified a very strong association be-
tween flucloxacillin- induced liver injury and HLA- B * 57:01, which was 
subsequently replicated in independent cohorts with an odds ratio 
of 80.82 Currently, some experts advocate using HLA genotyping in 
flucloxacillin- treated patients who develop cholestasis as a diagnostic 
biomarker to help exclude the drug as a suspect agent (ie high nega-
tive predictive value).83 More recently, Nicoletti et al demonstrated 
that HLA- A * 33:01 was a risk factor for cholestatic and mixed DILI in 
Caucasians from a number of drugs, including terbinafine, fenofibrate 
and ticlopidine.21 Finally, we recently showed that HLA- B *35:02 was 
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over- represented in Caucasian patients with minocycline hepatotox-
icity.84 However, due to the small number of minocycline cases, repli-
cation cohorts are needed to confirm the value of testing for this allele 
in minocycline- treated patients presenting with liver injury.
Limitations in the current utilization of DILI biomarkers include 
(a) limited knowledge of performance characteristics of the tests 
in patients with idiosyncratic DILI versus other causes of liver in-
jury and (b) lack of standardized assay methods and normal values. 
Nonetheless, novel biomarkers represent an exciting opportunity 
for us to improve the detection, prognostication and even treatment 
of patients at risk for severe idiosyncratic DILI.
10  | SUMMARY
Although DILI is an uncommon cause of liver injury associated with 
a variety of clinical phenotypes, substantial progress into the aeti-
ologies, natural history and treatment of DILI has been made. Host 
demographic (age, gender, race), clinical (diabetes) and laboratory 
features (serum ALT, bilirubin, INR) at DILI onset have been associ-
ated with the severity and outcomes of liver injury in DILI patients. 
Pilot studies suggest that medical interventions such as the use of 
n- acetylcysteine and corticosteroids may provide benefit to some 
patients, but additional studies are needed. Lastly, the application of 
powerful genomic, proteomic and transcriptomic technologies holds 
promise to identify improved diagnostic, prognostic and mechanistic 
biomarkers that will enhance our understanding of DILI susceptibility 
and outcomes.
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